RESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures

Inclusion criteria

• Subject is a postmenopausal female at least 1-year post menses and at least 65 years of age and less than 92 years of age.
• Subject presents with a low-energy index fragility hip fracture in one hip and will undergo surgical repair of the fractured hip.
• Subject has at least one of the following additional risk factors for a secondary hip fracture (as determined by subject or legally authorized representative (LAR) interview or medical record review):
• Documented falls assessment indicating subject is at moderate or high risk of falls
• Falls history (2 or more falls in the previous 12 months)
• History of vertigo, dizziness, or postural hypotension
• Documented T-score \< -2.5 at the hip
• Taking more than 3 daily prescription medications
• Visual impairment as confirmed by one of the following:
• Subject reports difficulty seeing
• Lack of depth perception or vision loss in one eye
• Macular degeneration
• Cataracts
• Prior non-hip fragility fracture
• Cognitive frailty as assessed by SPMSQ (mild cognitive impairment determined by SPMSQ ≤ to 4) or delirium
• Parkinson's disease stage 3 or 4
• 10-year hip fracture probability \>15% using the FRAX® Fracture Risk Assessment Tool of the clinical site country
• Subject is expected to be ambulatory after the hip fracture repair procedure. "Ambulatory" is defined as a patient's ability to ambulate beyond simple transfers with or without assistive devices.
• Informed consent is provided by the subject or the subject's LAR. Use of an LAR to obtain patient consent requires that the patient must understand and be able to participate in post operative restrictions and requirements.
• The subject's willingness, ability, and commitment to participate in screening, treatment, and all follow-up evaluations for the full duration of the study has been documented.

Exclusion criteria

• Criterion omitted
• Criterion omitted
• Subject is currently enrolled in another interventional clinical study affecting the target hip.
• Subject has a history of hip surgery or previous hip fracture on the target unfractured hip contralateral to the index hip fracture.
• Subject has new fractures in addition to the index hip fracture at admission that, in the opinion of the investigator, would further compromise patient mobility, rehabilitation, or recovery.
• Subject has an infection at the LOEP intended treatment site or has non-intact skin or acute traumatic injuries with open wounds close to the area of intended LOEP treatment.
• Subject has a progressive increase in undiagnosed pain in the target hip contralateral to the index fractured hip over the previous 3 months that in the opinion of the Investigator may suggest underlying bone or joint pathology on the unfractured side.
• Subject has radiological evidence of gross bony or joint pathology of the hip, including signs predictive of atypical femoral fractures (e.g. cortical beaking), or has been diagnosed and/or treated for atypical femoral fractures.
• Criterion omitted
• Subject has a history of metabolic bone disease other than osteoporosis (e.g., Paget's disease, renal osteodystrophy, or osteomalacia).
• Criterion omitted
• Subject has active cancer
• Criterion omitted
• Criterion omitted
• Criterion omitted
• Criterion omitted
• Criterion omitted
• Subject has end stage renal insufficiency defined as an estimated glomerular filtration rate (eGFR) \< 15 mL/min.
• Criterion omitted
• Criterion omitted
• Subject has moderate or severe cognitive impairment as assessed by an SPMSQ of 5 or higher.
• Subject has known allergies to calcium-based bone void fillers.
• In the judgement of the Investigator, the subject is not a good study candidate (e.g., poor mental health, or active drug or alcohol abuse issues), and or subject would not be a good candidate to undergo an ELECTIVE orthopedic surgical procedure such as a total hip arthroplasty in her current medical, physiological condition.
• Subject fails pre-operative or intraoperative eligibility criteria as specified in section 7.4.2. of the clinical investigation plan.